Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
Date:2/8/2010

Financial Results

For the six months ended December 31, 2009, revenues increased 44.1% to $28.3 million from $19.7 million reported for the prior year period. Ginkgo Mihuan, one of Tianyin's flagship products, contributed approximately $9.2 million or 33% of total revenues for the first six months of fiscal 2010, representing 102% year-over-year growth. Revenues generated from the Arpu Shuangxin Oral Liquid were $2.9 million, or 16% of total revenues, a 2% increase from fiscal 2009. Tianyin's top 5 selling products generated revenue of $14.7 million and represented 53% of total revenue.

Cost of goods sold for the first six months of fiscal year 2010 was approximately $13.5 million, yielding a gross profit of $14.8 million and gross margins of 52.3%, compared to $10.0 million in gross profit and a gross margin of 51.0% for the same period in fiscal year 2009.

Operating expenses for the first six months of fiscal year 2010 were $8.9 million, compared to $5.4 million in the same period in fiscal 2009. Selling, general and administration expenses for the period increased to approximately $8.5 million from $5.2 million, which included the previously disclosed non-cash equity compensation expense.

Operating income totaled approximately $5.9 million, a 27.1% increase from the $4.6 million reported for the first half of fiscal 2009. Operating margins were 20.8% and 23.6% for the first half of fiscal year 2010 and 2009, respectively, and were impacted by a non r
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
3. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
4. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
7. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
9. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
10. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Corporation,s (Amex: ETC ) ("ETC" or the ... contract with the Netherlands,Institute for Safety, NIFV, to ... Simulator for Aircraft Rescue Fire Fighting., The ... military helicopter,scenario consisting of AH-64 Apache helicopters parked ...
... FRANCISCO, Calif., Nov. 3 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... enrollment,in a large Phase II clinical trial ... inhibitor anticoagulant, for stroke prevention in patients ...
... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today announced it has started,a Phase ... enzyme,(rHuPH20) co-formulations with Humulin(R) R (regular insulin ... Type 1 diabetic,patients. This study is designed ...
Cached Biology Technology:Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 2Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
(Date:8/28/2014)... news release is available in German . ... water fish, owes its name to a striking pattern of ... types, black cells, reflective silvery cells, and yellow cells emerge ... and arrange as a multilayered mosaic to compose the characteristic ... three cell types have to interact to form proper stripes, ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... in German . , Researchers at the Max ... the Czech Academy of Sciences in Prague have developed a new ... acids, amino acids and other organic substances from plant or animal ... liter -- is sufficient to identify certain blood related metabolites. ...
... of fishing gear could help the world,s coral reefs and their ... team of scientists led by Dr Josh Cinner of the ARC ... has proposed that bans on fishing gear - like spear guns, ... in the recovery of reefs and fish populations hard hit by ...
... Although worlds apart, the way fish learn could be ... a new research study. A common species of fish ... nine-spined stickleback, could be the first animal shown to exhibit ... compare the behaviour of other sticklebacks with their own experience ...
Cached Biology News:An easy way to find a needle in a haystack by removing the haystack 2An easy way to find a needle in a haystack by removing the haystack 3Gear bans 'can help save reefs' 2Gear bans 'can help save reefs' 3Common fish species has 'human' ability to learn 2Common fish species has 'human' ability to learn 3
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Request Info...
MOUSE ANTI HUMAN FACTOR I...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: